Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Deborah, Collyar"'
Autor:
Elissa M. Ozanne, Kellyn Maves, Angela C. Tramontano, Thomas Lynch, Alastair Thompson, Ann Partridge, Elizabeth Frank, Deborah Collyar, Desiree Basila, Donna Pinto, Terry Hyslop, Marc D. Ryser, Shoshana Rosenberg, E. Shelley Hwang, Rinaa S. Punglia
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-5 (2024)
Abstract Background The heterogeneous biology of ductal carcinoma in situ (DCIS), as well as the variable outcomes, in the setting of numerous treatment options have led to prognostic uncertainty. Consequently, making treatment decisions is challengi
Externí odkaz:
https://doaj.org/article/945c187b75fb456dbde65e04441ae27c
Autor:
E.G. Engelhardt, R.S.J.M. Schmitz, M.A. Gerritsma, C.M.T. Sondermeijer, E. Verschuur, J.H.E. Houtzager, R. Griffioen, N. Bijker, R.M. Mann, V. Retèl, F.H. van Duijnhoven, J. Wesseling, E.M.A. Bleiker, Alastair Thompson, Serena Nik-Zainal, Elinor J. Sawyer, Helen Davies, Andrew Futreal, Nicholas Navin, E. Shelley Hwang, Jos Jonkers, Jacco van Rheenen, Fariba Behbod, Esther H. Lips, Marjanka Schmidt, Lodewyk F.A. Wessels, Daniel Rea, Proteeti Bhattacharjee, Hilary Stobart, Deborah Collyar, Donna Pinto, Marja van Oirsouw, S. Alaeikhanehshir, L. Elshof
Publikováno v:
Breast, Vol 77, Iss , Pp 103764- (2024)
Background: Ductal carcinoma in situ (DCIS) can progress to invasive breast cancer (IBC), but often never will. As we cannot predict accurately which DCIS-lesions will or will not progress to IBC, almost all women with DCIS undergo breast-conserving
Externí odkaz:
https://doaj.org/article/bc84270199394f7bb7028854a77ee924
Autor:
James L Gulley, Deborah Collyar, Pedro J Romero, Christian M Capitini, Leisha A Emens, Avery D Posey, Patrick Hwu, Jennifer A Wargo, Ann W Silk, Ana Carrizosa Anderson, Tullia C Bruno
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 6 (2024)
Cancer immunotherapy has flourished over the last 10–15 years, transforming the practice of oncology and providing long-term clinical benefit to some patients. During this time, three distinct classes of immune checkpoint inhibitors, chimeric antig
Externí odkaz:
https://doaj.org/article/ba0feaa1364741509df21dfe108b7d2c
Autor:
David Cella, Chieh-I Chen, Ruben G. W. Quek, Ainhoa Uribarren, Matthew Reaney, Vera Mastey, Deborah Collyar, Olivier Chassany
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Introduction: Regulatory agencies encourage the incorporation of the patient voices throughout clinical drug development. Patient-Reported Outcomes (PROs) offer one way of doing this and their use has markedly increased in many therapeutic areas, par
Externí odkaz:
https://doaj.org/article/17a05f7495ab4221b6482f1915164555
Autor:
Sena Alaeikhanehshir, Ellen G. Engelhardt, Frederieke H. van Duijnhoven, Maartje van Seijen, Patrick A. Bhairosing, Donna Pinto, Deborah Collyar, Elinor Sawyer, Shelley E. Hwang, Alastair M. Thompson, Jelle Wesseling, Esther H. Lips, Marjanka K. Schmidt
Publikováno v:
Breast, Vol 50, Iss , Pp 95-103 (2020)
Objective: The majority of ‘low-risk’ (grade I/II) Ductal Carcinoma In Situ (DCIS) may not progress to invasive breast cancer during a women’s lifetime. Therefore, the safety of active surveillance versus standard surgical treatment for DCIS is
Externí odkaz:
https://doaj.org/article/b800c69886634c58ac9c9fedd17ea552
Autor:
Janet L. Wale, David Chandler, Deborah Collyar, Dominique Hamerlijnck, Roberto Saldana, Zack Pemberton-Whitely
Publikováno v:
Frontiers in Medical Technology, Vol 3 (2022)
Health technology assessment (HTA) is intended to determine the value of health technologies and, once a technology is recommended for funding, bridge clinical research and practice. Understanding the values and beliefs expressed by patients and heal
Externí odkaz:
https://doaj.org/article/ba5a125b5cb84133b3f505418ef76c9d
Autor:
Derek F. Amanatullah, John S. Tamaresis, Pauline Chu, Michael H. Bachmann, Nhat M. Hoang, Deborah Collyar, Aaron T. Mayer, Robert B. West, William J. Maloney, Christopher H. Contag, Bonnie L. King
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-16 (2017)
Abstract Background Approximately 70% of all breast cancers express the estrogen receptor, and are regulated by estrogen. While the ovaries are the primary source of estrogen in premenopausal women, most breast cancer is diagnosed following menopause
Externí odkaz:
https://doaj.org/article/19b0a1c374384976a50affc318f9b6a8
Autor:
Deborah Collyar, Mathilde Matthea Machteld Almekinders, Jos Jonkers, Charlotta Mulder, Esther Lips
Publikováno v:
Nature Reviews Cancer. 22:663-678
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c2bffe3200f8f9fdd29252bd7d620e4
https://doi.org/10.1038/s41568-022-00512-y
https://doi.org/10.1038/s41568-022-00512-y
Autor:
Jonathan H. Shepherd, Karla Ballman, Mei-Yin C. Polley, Jordan D. Campbell, Cheng Fan, Sara Selitsky, Aranzazu Fernandez-Martinez, Joel S. Parker, Katherine A. Hoadley, Zhiyuan Hu, Yan Li, Matthew G. Soloway, Patricia A. Spears, Baljit Singh, Sara M. Tolaney, George Somlo, Elisa R. Port, Cynthia Ma, Charles Kuzma, Eleftherios Mamounas, Mehra Golshan, Jennifer R. Bellon, Deborah Collyar, Olwen M. Hahn, Clifford A. Hudis, Eric P. Winer, Ann Partridge, Terry Hyslop, Lisa A. Carey, Charles M. Perou, William M. Sikov
Publikováno v:
Journal of Clinical Oncology. 40:1323-1334
PURPOSE CALGB 40603 ( NCT00861705 ), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin and cyclophosphamide significantly increased the pathologic complete respon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20250b3ae5cffe96b72728d67c77ca14
https://doi.org/10.1200/jco.21.01506
https://doi.org/10.1200/jco.21.01506
Autor:
Tori Kinamon, Ramya Gopinath, Ursula Waack, Mark Needles, Daniel Rubin, Deborah Collyar, Sarah B Doernberg, Scott Evans, Toshimitsu Hamasaki, Thomas L Holland, Jessica Howard-Anderson, Henry Chambers, Vance G Fowler, Sumati Nambiar, Peter Kim, Helen W Boucher
Publikováno v:
Clinical Infectious Diseases.
Background Desirability of outcome ranking (DOOR) is a novel approach to clinical trial design that incorporates safety and efficacy assessments into an ordinal ranking system to evaluate overall outcomes of clinical trial participants. Here, we deri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a76a40f39134e5021564219c5f4cae72
https://doi.org/10.1093/cid/ciad239
https://doi.org/10.1093/cid/ciad239